US FDA Puts Mirati’s KRAS Challenge To Amgen In The Slow Lane

Regulator's Decision Slated For December 2022

 
• By Ayisha Sharma
Chess pieces in different lanes, symbolizing a race,
While Amgen Won The Race To Launch, Mirati Claims Its Candidate Could Be Best In Class • Source: Alamy

More from Anticancer

More from Therapeutic Category